High density lipoprotein future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{HDL}} {{CMG}}; {{AE}} {{AN}}; {{RT}} ==Overview== Promising future therapies include CETP inhibitors which are currently in the experimental phase. A combination ...") |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Promising future therapies include CETP inhibitors which are currently in the experimental phase. A combination therapy with [[statins]] and [[ACE inhibitors]] is also a safe option in patients with [[HDL]] levels who also share features with [[dysmetabolic syndrome]]. However, the preventive effects of these two drugs tend to be cumulative. | Promising future therapies include CETP inhibitors which are currently in the experimental phase. A combination therapy with [[statins]] and [[ACE inhibitors]] is also a safe option in patients with [[HDL]] levels who also share features with [[dysmetabolic syndrome]]. However, the preventive effects of these two drugs tend to be cumulative<ref name="pmid12821213">{{cite journal |author=Liem AH, Jukema JW, van Veldhuisen DJ |title=Secondary prevention in coronary heart disease patients with low HDL: which options do we have? |journal=[[International Journal of Cardiology]] |volume=90 |issue=1 |pages=15–21 |year=2003 |month=July |pmid=12821213 |doi= |url=}}</ref>. | ||
==References== | |||
{{Reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Cardiology]] | |||
[[Category:Lipid disorders]] | |||
[[Category:Lipoproteins]] | |||
Revision as of 20:19, 26 April 2013
Template:HDL Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
Promising future therapies include CETP inhibitors which are currently in the experimental phase. A combination therapy with statins and ACE inhibitors is also a safe option in patients with HDL levels who also share features with dysmetabolic syndrome. However, the preventive effects of these two drugs tend to be cumulative[1].
References
- ↑ Liem AH, Jukema JW, van Veldhuisen DJ (2003). "Secondary prevention in coronary heart disease patients with low HDL: which options do we have?". International Journal of Cardiology. 90 (1): 15–21. PMID 12821213. Unknown parameter
|month=ignored (help)